These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10080242)

  • 41. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation of D1, but not D2 receptors potentiates dizocilpine-mediated disruption of prepulse inhibition of the startle.
    Bortolato M; Aru GN; Fà M; Frau R; Orrù M; Salis P; Casti A; Luckey GC; Mereu G; Gessa GL
    Neuropsychopharmacology; 2005 Mar; 30(3):561-74. PubMed ID: 15328529
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
    Tidey JW; Bergman J
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of selective dopamine D1- and D2-agonists and antagonists on timing performance in rats.
    Frederick DL; Allen JD
    Pharmacol Biochem Behav; 1996 Apr; 53(4):759-64. PubMed ID: 8801575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The full D1 dopamine receptor agonist SKF-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors.
    Wang JQ; McGinty JF
    J Pharmacol Exp Ther; 1997 May; 281(2):972-82. PubMed ID: 9152408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholecystokinin, dopamine D2 and N-methyl-D-aspartate binding sites in the nucleus of the solitary tract of the rat: possible relationship to ingestive behavior.
    Qian M; Johnson AE; Källström L; Carrer H; Södersten P
    Neuroscience; 1997 Apr; 77(4):1077-89. PubMed ID: 9130789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stimulating dopamine D1 receptors increases the locomotor activity of developing rats.
    Shieh GJ; Walters DE
    Eur J Pharmacol; 1996 Sep; 311(2-3):103-7. PubMed ID: 8891588
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cocaine induced T cell proliferation in the rat: role of amygdala dopamine D1 receptors.
    Caroleo MC; Arbirio M; Di Francesco P; Pulvirenti L; Garaci E; Nistico G
    Neurosci Lett; 1998 Nov; 256(2):61-4. PubMed ID: 9853703
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats.
    Wirtshafter D; Osborn CV
    Eur J Pharmacol; 2005 Dec; 528(1-3):88-94. PubMed ID: 16324697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha 2 noradrenoceptors in the anterior piriform cortex decline with acute amino acid deficiency.
    Gietzen DW; Jhanwar-Uniyal M
    Brain Res Mol Brain Res; 1996 Jan; 35(1-2):41-6. PubMed ID: 8717338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of specific dopaminergic agonists and antagonists in the open-field test.
    Bruhwyler J; Chleide E; Liégeois JF; Delarge J; Mercier M
    Pharmacol Biochem Behav; 1991 Jun; 39(2):367-71. PubMed ID: 1682946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
    Rossi NF
    Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
    Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
    J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
    Lindgren HS; Ohlin KE; Cenci MA
    Neuropsychopharmacology; 2009 Nov; 34(12):2477-88. PubMed ID: 19606087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polydipsia and dopamine: behavioral effects of dopamine D1 and D2 receptor agonists and antagonists.
    Mittleman G; Rosner AL; Schaub CL
    J Pharmacol Exp Ther; 1994 Nov; 271(2):638-50. PubMed ID: 7965779
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sleep during acute dopamine D1 agonist SKF 38393 or D1 antagonist SCH 23390 administration in rats.
    Monti JM; Fernández M; Jantos H
    Neuropsychopharmacology; 1990 Jun; 3(3):153-62. PubMed ID: 2141985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dopamine receptor agonists modulate voluntary alcohol intake independently of individual levels of alcohol intake in rats.
    Spoelder M; Baars AM; Rotte MD; Vanderschuren LJ; Lesscher HM
    Psychopharmacology (Berl); 2016 Jul; 233(14):2715-25. PubMed ID: 27236784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effects of l-stepholidine on the peripheral vascular dopamine DA1 and DA2 receptor subtypes].
    Zhang W; Zhi J; Guo W; Zhao R; Jin G
    Yao Xue Xue Bao; 1998 Oct; 33(10):721-6. PubMed ID: 12016922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The CCK-A receptor antagonist, devazepide, blocks the anorectic action of CCK but not peripheral serotonin in rats.
    Eberle-Wang K; Simansky KJ
    Pharmacol Biochem Behav; 1992 Nov; 43(3):943-7. PubMed ID: 1448490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence for the sensitivity of operant timing behaviour to stimulation of D1 dopamine receptors.
    Cheung TH; Bezzina G; Hampson CL; Body S; Fone KC; Bradshaw CM; Szabadi E
    Psychopharmacology (Berl); 2007 Dec; 195(2):213-22. PubMed ID: 17668188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.